|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 11400 Rockville Pike |
Address2 |
|
| City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly Corredor |
Date | 4/18/2021 7:08:31 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment
Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine
Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act
Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)
Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.
Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan
Discussion with ONDCP staff regarding drug policy priorities in 2021
Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders
Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency
Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions
Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities
Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years
Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers
Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment
Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine
Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act
Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)
Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.
Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan
Discussion with ONDCP staff regarding drug policy priorities in 2021
Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders
Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency
Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions
Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities
Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years
Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers
Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment
Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine
Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act
Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)
Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.
Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan
Discussion with ONDCP staff regarding drug policy priorities in 2021
Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders
Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency
Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions
Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities
Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years
Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers
Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment
Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine
Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act
Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)
Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.
Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan
Discussion with ONDCP staff regarding drug policy priorities in 2021
Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders
Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency
Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions
Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities
Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years
Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers
Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment
Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine
Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act
Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)
Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.
Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan
Discussion with ONDCP staff regarding drug policy priorities in 2021
Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders
Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency
Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions
Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities
Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years
Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers
Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment
Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine
Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act
Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)
Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.
Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan
Discussion with ONDCP staff regarding drug policy priorities in 2021
Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders
Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency
Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions
Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities
Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years
Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers
Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |